Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Isocitrate dehydrogenase 1 (IDH1) is a critical metabolic enzyme located in the cytoplasm and peroxisomes that catalyzes the reversible oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), producing NADPH in the process (UniProt O75874). While the wild-type enzyme maintains cellular redox balance and supports lipid synthesis, specific somatic mutations—most frequently at the R132 residue—grant the enzyme a neomorphic gain-of-function (Nature, 2009, 462:739-744). This mutant form converts α-KG into the oncometabolite D-2-hydroxyglutarate (2-HG), which competitively inhibits α-KG-dependent dioxygenases, including histone demethylases and TET family DNA hydroxylases (PubMed, 23412291). The resulting epigenetic hypermethylation leads to impaired cellular differentiation and promotes the development of various malignancies such as acute myeloid leukemia, low-grade gliomas, and cholangiocarcinoma (FDA, Tibsovo Prescribing Information). Pharmacological targeting of mutant IDH1 with small-molecule inhibitors aims to lower 2-HG levels, thereby restoring normal epigenetic signaling and inducing the differentiation of malignant cells (StatPearls, NBK545234). These inhibitors are specifically designed to bind the mutant protein, though some dual inhibitors also target the related IDH2 isoform or show varying degrees of selectivity against the wild-type enzyme (Nature Reviews Cancer, 2017, 17:71-83). Clinical management of patients on these therapies requires monitoring for differentiation syndrome, a potentially fatal condition characterized by rapid proliferation and differentiation of myeloid cells (FDA, Rezlidhia Label).
Small-molecule inhibition of the mutant IDH1 enzyme to suppress the production of the oncometabolite D-2-hydroxyglutarate (2-HG), thereby reversing epigenetic dysregulation and promoting cellular differentiation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Isocitrate dehydrogenase [NADP] cytoplasmic (IDH1) (IDH1).